IRADIMED CORP Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by IRADIMED CORPORATION on January 22, 2018. The report serves as a current disclosure regarding the company's financial results and guidance. The filing incorporates by reference a press release (Exhibit 99.1) containing revenue estimates for the fourth quarter and full year 2017, as well as financial guidance for the full year and first quarter of 2018.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1) and are not explicitly detailed in the body of this 8-K document.
Material Changes and Guidance
The primary purpose of this filing is to disclose Regulation FD information regarding:
- Revenue estimates for the fourth quarter and full year 2017.
- Financial guidance for the full year and first quarter of 2018.
The filing explicitly states that the information in Items 2.02 and 7.01, including the attached exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 22, 2018) for specific revenue estimates and guidance figures.
- Verify the actual fourth quarter and full year 2017 financial results against the estimates provided in the press release.
- Assess the company's emerging growth company status and its election not to use the extended transition period for new accounting standards.
- Note that the guidance and estimates in this filing are not legally "filed" under Section 18 of the Exchange Act.